Fail­ure-prone Unum cuts jobs, los­es sci­en­tif­ic chief, and changes fo­cus yet again

6 years ago
R&D
Cell/Gene Tx

Bio­gen’s ear­ly R&D chief ex­its for ARCH and Be­zos-backed an­ti-ag­ing biotech

6 years ago
R&D

With one ri­val down, No­var­tis-part­nered biotech scores $100M round to fund mid-stage tri­als of fi­bro­sis drug

6 years ago
Financing

'Un­heard-of speed­s': Trump, new­ly warmed up to bio­phar­ma, prais­es in­dus­try's coro­n­avirus re­sponse at White House ...

6 years ago
Coronavirus

In record-set­ting set­tle­ment, No­var­tis’ San­doz unit ad­mits guilt in con­spir­a­cy to fix prices

6 years ago
R&D

Hap­py alone Qi­a­gen changes course af­ter Ther­mo Fish­er of­fers to buy it in $11.5B deal

6 years ago
Deals

Ver­tex, Seat­tle Ge­net­ics, Alpine with­draw from in­vestor con­fer­ence as biotechs brace for coro­n­avirus

6 years ago
People
Coronavirus

End­ing a gru­el­ing 10-year drought, Sanofi fi­nal­ly wins an OK for an in-house can­cer drug

6 years ago
R&D

No­var­tis re­it­er­ates its faith in Eylea ri­val Beovu; An­ti-NGF drug from Lil­ly, Pfiz­er is ac­cept­ed for FDA re­view

6 years ago
News Briefing

Karyopharm spot­lights PhI­II re­sults af­ter con­tro­ver­sial FDA ap­proval

6 years ago
R&D
Pharma

Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

6 years ago
R&D

Cer­tain GSK an­tibi­ot­ic brands are up for sale — re­port

6 years ago
R&D

As US di­als up coro­n­avirus re­sponse, BIO taps Vir's George Scan­gos to head com­mit­tee co­or­di­nat­ing in­dus­try ef­forts

6 years ago
People
Coronavirus

In pos­si­ble sign of things to come, Daniel O’Day’s new-look Gilead bets $4.9B on can­cer biotech

6 years ago
Deals

Mor­phoSys’ off-the-shelf ri­val to CAR-T ap­proach­es fin­ish line with a speedy re­view

6 years ago
R&D

Wood­ford who? TCR-fo­cused Im­muno­core sol­diers on with $130M+ B round

6 years ago
Financing
Cell/Gene Tx

Ex ni­hi­lo: Take­da leads $100M+ round to fund biotech's sneak at­tack on tu­mors, pro­pelling new IL-2, CT­LA-4 drugs to ...

6 years ago
Financing
Startups

The FDA OKs gener­ic Dara­prim, the Mar­tin Shkre­li ther­a­py that trig­gered an un­end­ing tem­pest over drug pric­ing

6 years ago
Pharma

Scoop: Cor­po­rate de­vel­op­ment chief hits the ex­it at Bio­gen as ad­u­canum­ab jit­ters roll on

6 years ago
People
R&D

Why FDA can’t dis­close the first coro­n­avirus-re­lat­ed drug short­age

6 years ago
Pharma
FDA+

Af­ter the field left her be­hind, a sci­en­tist-turned-in­vestor gets her first R&D job; Nous­com finds new lead­er­ship for ...

6 years ago
Peer Review

Sage con­firms sus­pen­sion of 2 de­pres­sion tri­als af­ter PhI­II flop; Es­pe­ri­on fol­lows up maid­en ap­proval with com­bo OK

6 years ago
News Briefing

Turn­ing fo­cus to clin­i­cal work, Ve­rastem ax­es 31 jobs, scales back can­cer drug pro­mo­tion af­ter dis­ap­point­ing sales

6 years ago
People
R&D

Ex-Sanofi chief Olivi­er Brandi­court, cur­rent Black­stone ad­vi­sor, jumps on Al­ny­lam board

6 years ago
People
First page Previous page 857858859860861862863 Next page Last page
A service from the Financial Times